NeuroVive Pharmaceutical AB Beta
Was ist das Beta von NeuroVive Pharmaceutical AB?
Beta von NeuroVive Pharmaceutical AB ist 0.93
Was ist die Definition von Beta?
BETA gibt an, ob eine Aktie mehr oder weniger schwankungsanfällig ist als der Gesamtmarkt. Ein Beta von weniger als 1 zeigt an, dass die Aktie weniger schwankungsanfällig ist als der Markt, während ein Beta von mehr als 1 anzeigt, dass die Aktie mehr schwankungsanfällig ist. Die Schwankungsanfälligkeit wird als Schwankung des Preises um den Mittelwert gemessen.
Beta is a measure of the risk arising from exposure to general market movements as opposed to idiosyncratic factors. The market portfolio of all investable assets has a beta of exactly 1. A beta below 1 can indicate either an investment with lower volatility than the market, or a volatile investment whose price movements are not highly correlated with the market. A beta greater than one generally means that the asset both is volatile and tends to move up and down with the market. Beta is important because it measures the risk of an investment that cannot be reduced by diversification. It does not measure the risk of an investment held on a stand-alone basis, but the amount of risk the investment adds to an already-diversified portfolio. In the capital asset pricing model, beta risk is the only kind of risk for which investors should receive an expected return higher than the risk-free rate of interest.
Beta von Unternehmen in Miscellaneous Sektor auf LSE im Vergleich zu NeuroVive Pharmaceutical AB
Was macht NeuroVive Pharmaceutical AB?
Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in Phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
Unternehmen mit beta ähnlich NeuroVive Pharmaceutical AB
- Megasoft hat Beta von 0.93
- Manitex International Inc hat Beta von 0.93
- Premier Gold Mines hat Beta von 0.93
- Premier Gold Mines hat Beta von 0.93
- Premier Gold Mines hat Beta von 0.93
- BAIC Motor hat Beta von 0.93
- NeuroVive Pharmaceutical AB hat Beta von 0.93
- iCar Asia hat Beta von 0.93
- Wesbanco hat Beta von 0.93
- Sumitomo Mitsui Inc hat Beta von 0.93
- Midnight Sun Mining hat Beta von 0.93
- Bio-Rad Laboratories hat Beta von 0.93
- Foncière Euris SA hat Beta von 0.93